Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Schiff

Showing results (291-300 of 305) with videos related to

Pageof 31
Sort By:
European Journal of Cancer (Oxford, England : 1990)|May 22, 2012
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modalityRoger Stupp, Eric T Wong, Andrew A Kanner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2026
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform TrialPatrick Y Wen, Donald A Berry, Meredith B Buxton, et al.
Neuro-Oncology|June 4, 2011
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumorsAndrew B Lassman, Fabio M Iwamoto, Timothy F Cloughesy, et al.
Neuro-Oncology|June 5, 2012
Initial treatment patterns over time for anaplastic oligodendroglial tumorsKatherine S Panageas, Fabio M Iwamoto, Timothy F Cloughesy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2026
Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform TrialPatrick Y Wen, Donald A Berry, Meredith B Buxton, et al.
Neuro-Oncology|July 6, 2014
Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumorsKatherine S Panageas, Anne S Reiner, Fabio M Iwamoto, et al.
Neuro-Oncology|October 14, 2022
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directionsJulie J Miller, L Nicolas Gonzalez Castro, Samuel McBrayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 8, 2024
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform NeurofibromaChristopher L Moertel, Angela C Hirbe, Hans H Shuhaiber, et al.
Neuro-Oncology|April 25, 2020
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directionsPatrick Y Wen, Michael Weller, Eudocia Quant Lee, et al.
Pageof 31

Showing results (291-300 of 305) with videos related to

Sort By:
Pageof 31
European Journal of Cancer (Oxford, England : 1990)|May 22, 2012
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modalityRoger Stupp, Eric T Wong, Andrew A Kanner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2026
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform TrialPatrick Y Wen, Donald A Berry, Meredith B Buxton, et al.
Neuro-Oncology|June 4, 2011
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumorsAndrew B Lassman, Fabio M Iwamoto, Timothy F Cloughesy, et al.
Neuro-Oncology|June 5, 2012
Initial treatment patterns over time for anaplastic oligodendroglial tumorsKatherine S Panageas, Fabio M Iwamoto, Timothy F Cloughesy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2026
Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform TrialPatrick Y Wen, Donald A Berry, Meredith B Buxton, et al.
Neuro-Oncology|July 6, 2014
Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumorsKatherine S Panageas, Anne S Reiner, Fabio M Iwamoto, et al.
Neuro-Oncology|October 14, 2022
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directionsJulie J Miller, L Nicolas Gonzalez Castro, Samuel McBrayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 8, 2024
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform NeurofibromaChristopher L Moertel, Angela C Hirbe, Hans H Shuhaiber, et al.
Neuro-Oncology|April 25, 2020
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directionsPatrick Y Wen, Michael Weller, Eudocia Quant Lee, et al.
Pageof 31